Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Medivir, Audiocast with teleconference, Q3'24

By Inderes11/6/2024, 1:00 PM
Medivir

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Pia Baumann
00:00 - 02:48

Thank you and good afternoon. Good morning everyone, and welcome to the Medivir Q3 report. We are thrilled to walk you through some of the events of the past quarter. We've seen a lot of progress in our lead asset, Fostrox, especially over the last couple of weeks. So we look forward to going through the bigger events as we aim to bring the first oral liver-targeted treatment for patients with advanced liver cancer to market. In terms of key events during the past quarter, and as we presented earlier in September at the ESMO Congress, we showcased a mature data set from an efficacy standpoint, confirming the promise of improved outcomes with the combination of Fostrox and Lenvima. This included, among other things, a 10.9-month mature data set with regards to time to progression, which is substantially longer than what can be expected with current second-line treatment alternatives. So, further strengthening our belief in the combination as a treatment option for the future, Pia will go through in a bit more detail what we shared at ESMO and the feedback we received from the scientific community. Secondly, and importantly, earlier this week we were able to announce the clinical trial collaboration that we have now signed with Eisai. This further validates the potential of the combination of Fostrox and Lenvima. As part of this agreement, we'll discuss this further and form a joint development committee with Eisai. And we are very pleased to be working with them moving forward while still retaining the full rights to the asset. And thirdly, and equally importantly, we had our monotherapy data published in the Journal of Hepatocellular Carcinoma, sort of highlighting to the world the proof of concept of Fostrox as a liver-targeted treatment for cancer in the liver. It's been a good quarter, and in the room with me today. Apart from myself, Pia Baumann, our Chief Medical Officer, will also be going through some of our experience and data from ESMO. Part of the Q&A and Magnus, who is our CFO, will, of course, go through the financial highlights. Fredrik Öberg, our CFO, is with us in the room for the Q&A session as well. So with that, let's look back and take us back a couple of months to the exciting data presentations that we had at ESMO, Pierre.

Jens Lindberg
02:49 - 13:39

Thank you and good afternoon. So we now have mature data in this study that was presented at ESMO, with a median time of follow-up of 10.5 months. And this is the combination of Fostrox and Lenvima. And as Jens already said, we presented it, and it really confirms what we have shown before about the promise of efficacy. So we can go to the next slide. So at ESMO, the data that was presented there, I would just start by saying it mainly focused on first-line treatment in advanced liver cancer. And one of those who presented this pointed out that there are now eight different regimens in the first line setting, and none of those who were there really know what to do after. While the focus should really be on second-line treatment and beyond. And one of the investigators in our ongoing study, Dr. Hong Jae Chon from Korea, has certainly focused on second-line treatment and has recently, in several publications, provided data, real-world data from his clinic for Lenvima as monotherapy and second line. So in order to put our data that we have presented at ESMO but also at ESMO GI from Fostrox in combination with Lenvima into context, we invited Dr. Hong Jae Chon to a WebEx during ESMO, which some of you attended, where he shared his experience from treating patients with Lenvima as monotherapy at his clinic, and compared those data with the outcomes of patients treated with Fostrox plus Lenvima in our study. You can go to the next slide. So just as a reminder, I know we have shown this before, the Fostrox plus Lenvima study consisted of first a dose escalation part followed by a dose expansion part where we ended up at the dose of 30 mg. Fostrox is taken orally once daily for five days in a 21-day cycle, alongside Lenvima, which is taken once daily without interruption at the approved standard doses. Patients were recruited at 15 different sites across Europe and Asia. We can go to the next slide. So I already mentioned that, but we have a mature median follow-up. So, the median time of follow-up was 10.5 months for this study. The median time to progression is now almost 11 months, with a response rate of 24% and a disease control rate of 81%. And what is very interesting is that the patients in this study have been staying much longer than what we expected, with three patients still ongoing in the ongoing study and one patient still in response after two years of treatment. So when we talked about this data at ESMO, it generated a very positive response in the scientific community. And this also generated an increased interest in participating in the upcoming and planned phase 2B study. So with this median time of progression of 10.9 months, we can go to the next slide, which is substantially longer. It compares favorably with all other relevant datasets in second-line HCC. And what you can see to the right on this slide is 13 second-line studies, where we can see a median time to progression around four months. And this is regardless if it is with Lenvima after an IO or mono, or with other kinase inhibitors, or with immunotherapy combinations. So we can go to the next slide. As previously mentioned, we had this WebEx which provided the context in which Dr. Sean presented data from his publication, comparing Sorafenib and Lenvatinib in a relatively large dataset. This is a real-world study where he could demonstrate that Lenvatinib was significantly more effective than Sorafenib. But what he also did was take the Lenvatinib data from monotherapy and compare it with the data from the phase 1B Fostrox Lenvima study, in which he was an investigator. And that is what we discussed at this WebEx. So we can go to the next slide. What he showed was that this was true regardless of whether we are looking at time to progression, response rate, or disease control rate. As you can see here, the results with Fostrox plus Lenvima signaled superiority in second-line treatment. And according to his clinical experience, the response rate of Lenvima alone is not higher than 10% and the time to progression is usually somewhere around four months. Why? A TP of almost 11 months was very, very impressive. So, to achieve this kind of efficacy, Dr. Sean also presented safety data from the Fostrox plus Lenvima study. Our study presented at ESMO GI in June focused significantly on the safety, tolerability profiles, and earlier biopsies. We have shown previously that Fostrox, whether used as monotherapy or in combination with Lenvima, selectively kills tumor cells in the liver while sparing the normal liver cells. So this is what we observed, correct? We also need to examine this in the clinic. Is this true also in the clinic? Can we look at parameters in the liver that could confirm this? And we did. We confirmed in an analysis that liver enzymes and other laboratory data, in this case the albumin score, determine liver function. And they were stable during the treatment period. And this means that we preserve liver function, which enables an opportunity for durable efficacy. One additional tolerability parameter, which is really important for long-term treatment, is the impact on platelets and neutrophils that we have shown earlier. We expected them to be impacted somewhat, but the analysis showed that these values remained stable over time. And here you can see a ten-month follow-up where we have added all the laboratory analyses. Despite measuring neutrophils and thrombocytes throughout the treatment for all patients during all cycles, very few measurements indicated a level of grade three or higher. That is the only type of measurements that you can see below the orange line here. And this again enabled patients to stay on treatment long term. These data were presented at ESMO along with the mature efficacy data set that we discussed. All of these data can be found on the Medivir website. So what else have we been doing? We were recently at the International Liver Cancer Association's annual meeting in Toronto in October. And we were there also to understand the most recent developments and potential for upcoming changes in the treatment landscape and to meet with global experts as well as potential investigators in the planned phase two study. What we can say is that there was huge interest in meeting us to discuss our data and understand more about the upcoming study. Additionally, it is important to note, as I've mentioned before but must emphasize again, that new data in second-line HCC confirms the high need for alternatives in this patient population. Also, at ILCA, the main focus was trying to find out if systemic treatment, in addition to surgery in earlier stages and other local treatments in intermediate stages, could be a viable option. But none of this is ready for implementation, so there are no changes around the earlier stages of HCC that could potentially impact the development of Fostrox plus Lenvima. So the overall takeaway is that it is important to see new second-line treatment and that the development of Fostrox plus Lenvima has gained substantial interest and is considered as a new, promising option. John has already mentioned that, and we are excited about the combination. But we have also published the clinical proof of concept with Fostrox as monotherapy in the Journal of Hepatocellular Carcinoma, and the results from this study show that Fostrox was safe and tolerable with preliminary anti-tumor activity. Furthermore, it confirmed the liver-targeted and selective mechanism of action, as I already said with the biopsies. So the next step is the randomized phase two study that is really designed with the appropriate statistical power to show efficacy, benefit on overall response rate as the primary endpoint. And this is an endpoint that the FDA accepts for potential accelerated approval. And the aim is also to use this study to file for breakthrough therapy designation and to initiate an accelerated approval process. And before I leave it to Janet, I think that this study really provides us with the opportunity to truly make a meaningful impact for second-line liver cancer patients.

Pia Baumann
13:41 - 22:42

Thank you. Pia. And one critical element, clearly, of course, in advancing this program is to ensure that we have appropriate clinical trial supplies for a randomized phase of this size and magnitude. We were very happy to announce on Monday that we have now signed the clinical trial collaboration and supply agreement with Eisai. As part of that, they will then, of course, provide drug supply, which would otherwise require significant investment to support the full study. And while of course we still retain all the rights to the compound. What we will also do is establish a joint development committee with Eisai for the planning and execution of the study. We are quite happy with Eisai for making this commitment, as it generates quite a bit of work on their behalf in supporting the study. We are now embarking into additional countries in Asia, including the US, where they have had experience in the past. We truly believe that having this joint development with them will further support conducting the study in the most qualitative way possible, but also enable us to proceed at the highest possible speed. Clearly, we've had discussions with Eisai regarding the supply, and for them, supplying is not always straightforward. I mean, they enter into this kind of agreement if they believe that the study has the opportunity to deliver on its promise. The fact that they are engaging both from a supply perspective and a timing perspective is significant. So this further validates the potential of Fostrox in addition to Lenvima. And clearly they are the company that knows best. What benefit Lenvima alone provides. So we're quite happy with the confirmation and the belief in the combination. What the combination can provide on top of Lenvima. So, this means it is yet another step in our preparations for the randomized Phase 2B trial. And those preparations are proceeding according to plan. And as we've communicated earlier, we said that we're on track to open an IND in the US before the end of the year or in Q4. So things continue to move along quite nicely in the preparations. And just to reiterate a bit, one additional aspect we are observing is the significant unmet medical need that the PPA has highlighted. And we talk about the lack of treatment options in the second line, whereas there's quite a bit of focus on the first line. The other thing we see coming forth is that, unfortunately, the growth of liver cancer or the incidence of liver cancer is not slowing down. If anything, it's actually increasing. So what we observe is growth in both the West and the East, largely driven by the obesity epidemic and the fatty liver disease it causes. So what we foresee is clearly a commercial opportunity that is growing. So when we look to 2030, that commercial opportunity in the second-line market alone, again, where there are no approved treatment options today, will be valued in excess of 2.5 billion. If our treatment's duration aligns with the time to progression. We're seeing in the current study with Fostrox plus Lenvima, if that carries through and we assume a treatment option in line with that, then the value of that market actually increases further and starts to approach 4 billion. So the second line liver cancer market alone clearly has significant potential. And then, going forward, we can look to move it up in earlier treatment lines, potentially for liver metastases from other tumors. But if we just focus on second-line liver cancer where there are no treatment options today, it represents a significant commercial opportunity. And the other part I just want to take a step back and reflect on is that in oncology in general, if you look across tumor types, it's usually quite a competitive landscape, but second-line liver cancer is a bit different. So if I take a bit of time to walk through this slide, on the left hand side is the current treatment algorithm. And we've talked about this before, I think it's important to emphasize because it isn't changing, yet there is a change occurring. And there's a window that we have an opportunity to move into in first line today. All patients, I would argue, or almost all patients will receive an immunotherapy combination as a standard of care. Usually that's Tecentriq and Avastin. And that's been the case since 2021. There are a number of studies ongoing to evaluate other immunotherapy combinations in first line. So there are a number of regimens competing to win in first-line space. But patients who progress on an IO combination will move into second-line therapy. And they will need something different. So relying solely on immunotherapy presents a challenging and unsuccessful way forward. So they will need a different mechanism of action and a different approach to killing cancer cells in the second line. And still, there are no approvals. There is no scientific evidence to support which treatment to use in the second line. And the community is almost screaming for alternatives due to a lack of treatment options. So with the combination of Fostrox and Lenvima, there is an opportunity to move quickly and be the first approved option. This is because, when you look at the right hand side of the slide, which highlights the competitive landscape, you see, as if in the green field, that there are a number of immunotherapies being evaluated in the second line. But we've already seen from ASCO that that approach doesn't work. And you can probably try a number of different immunotherapies. and it will still show the same. That sort of challenge doesn't work. So if you want to go down a new route with a novel combination and a different mechanism of action, we are at the forefront from a development perspective. So again, one of the reasons why we are trying to move with speed, and one of the reasons why the external community and the colleagues are pushing us to get to phase 2B as quickly as we possibly can. So, with that, I will just summarize things. Well, hang on a bit, move the slide. So in short, it kind of summarizes in four different buckets. We are developing the first oral liver-targeted treatment. And we've shown that we are able to deliver the drug locally in the liver. And when delivered in the liver, it targets tumor cells. We kill tumor cells and not healthy liver cells. That translates to a substantially improved clinical benefit for patients in the second-line setting, including a 10.9-month time to progression. And on the bottom left, there is an opportunity to move with speed in order to become that first approved treatment option. Hence our planned global phase two b, and at the bottom right, we aim to seize the market opportunity that is projected to be valued at over 2.5 billion by the time we arrive. Another important factor is that we've observed strong willingness in the current study to recruit patients to the combination, meaning that upon approval, the resistance to commercial uptake would be very low. So with that, Magnus, we move to financials.

Magnus Christensen
22:42 - 24:53

Thank you. Jens. Please move to slide number 22, where you can see the financial summary for the third quarter and year-to-date September. And as always, I will briefly comment on the Q3 result. And all numbers are in millions as usual. The result and cash flow in Q3 are in line with our forecast. The turnover for quarter three amounts to around 1 million, which relates to royalty income for the seller. Other external expenses are higher compared to last year in the quarter and relate to the ongoing combination study. We still have patients ongoing. Three patients are mentioned, along with CMC costs and preparations for the next phase of Fostrox. As Jens and Pia mentioned earlier, personnel costs are a little higher and relate foremost to the shared savings program that was implemented in Q2 this year. The operating loss for Q3 is -46, which is higher than the loss last year in the same quarter, and relates primarily to clinical and CMC costs and preparation for the next phase of Fostrox. The cash flow from operating activities in Q3 amounts to -33, which is in line with our forecast for the quarter. And also, I would like to mention that in October, we announced the loan facility from Linc AB of up to 30 million SEK. And we are very satisfied with the support from our major shareholder, Linc AB. And as stated in the press release, the facility will only be used if needed as a secondary financing option. Priority will be given to other financing alternatives, such as equity financing or a partner. Indeed. And with our current cash as of the end of September being almost $93 million, plus the loan facility, we have an estimated cash run rate to Q4 2025, according to the current plan and current assumptions. And with this, I will hand back over to Jens.

Pia Baumann
24:54 - 25:02

And we will sort of, at this stage, close the presentation for now and open the call for Q&A.

Operator
25:08 - 25:28

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Joe Panzini from H.C. Wainwright. Please go ahead.

Unknown 1
25:31 - 26:07

Hey, everybody. Thanks for taking the question. A couple, if you don't mind. So first, on the Eisai collaboration, I want to talk about certain levels of importance from this with two different angles. So first, um, I guess if you can't talk numbers, can you talk maybe about levels of magnitude? So when you consider the Phase 2B cost of the upcoming randomized study, what is the cost of that? But more importantly, what are the potential cost savings that are coming from Eisai supplying Lenvatinib?

Pia Baumann
26:10 - 27:01

Well, let's put it this way: regarding the procurement, what I mean is, we've decided—and I'll say the following. I'll take a step back and say that we consciously decided to purchase Lenvatinib for the current study because we wanted the freedom to use the data as we saw fit. So we know that it's a sizable investment, and if we were to go out into the open market and buy Lenvatinib for the upcoming study, we would be looking at costs of 15 to 20 million US. So it is quite a significant saving from our side, or an investment from our side, or however you want to put it, but in terms of what we would normally pay, it actually equates to a cost of 15 to 20 million USD that we don't have to incur with this trial supply collaboration.

Unknown 1
27:03 - 27:22

No, that's very helpful. And I think that’s a very important highlight. From a logistical standpoint regarding the collaboration, it is clear that you maintain global rights for Fostrox. Just curious, does Eisai have any rights of first refusal or rights of first look?

Pia Baumann
27:22 - 27:23

No.

Unknown 1
27:26 - 27:31

Got it. Very simple. I. Yes, yes. No.

Unknown 2
27:31 - 27:31

That's perfect.

Pia Baumann
27:32 - 27:40

I'm feeling bad. I feel like maybe I should say something more, but no. And so, hence the retaining of the perfect answer.

Unknown 2
27:40 - 27:41

Yeah.

Unknown 1
27:43 - 28:05

You have options. Yes. You have all your options open, so. Great. Just a question on the phase 1-2a data. When you examine the neutrophil data, for example. We believe that's a promising impact. So, just curious, what are the error bars that are indicated? Can you describe whether there were any rescue treatments like Neulasta or Neupogen, or the frequency of that happening?

Jens Lindberg
28:06 - 29:13

First of all, I didn't mention that because we have abbreviated this since previously, we had no cases of febrile neutropenia. We had very few occasions during the full treatment time where, for example, patients experienced grade three neutropenia or thrombocytopenia. I was trying to illustrate that during this period, you were viewing ten months of treatment involving all the patients and all the measurements we had been conducting. Furthermore, the ones below the orange line were the only cases at grade three, which potentially could lead to a dose reduction or treatment interruption. And we only observed this in six patients overall throughout the treatment duration. So which means that it is perhaps something you didn't see, but it's like a temporary dip and then it recovers. So you can keep the treatment time and you can keep the dose, which is extremely encouraging. In a study like this, we aim for long-term treatment.

Unknown 1
29:15 - 29:59

No, that's very helpful, Pia. Thank you for that. And my last question, if you don't mind. And thanks for indulging me. Um, with regard to the competitive chart that you brought up, it sort of looked like a rainbow a bit. A little bit, but, um, I guess there's a bit of hand-waving going on here. But when you look to the future, can you envision obviously Fostrox has good combinability, and you talk about the left side of the chart with the different immunotherapies being not that effective or not effective at all. Could you envision potential combinability with immunotherapies and, you know, the ability to say resensitize or any potential mechanisms for combinability that you could explore in the future?

Jens Lindberg
29:59 - 30:58

In theory, everyone is looking at this, trying to resensitize after becoming resistant to an immunotherapy combination. So that is what is going on right now. We can see that and it has not been successful, as I think it was either Jens or myself who said, it was a study involving regorafenib and pembrolizumab at ASCO, which was negative. So what they are trying to do then is to find something that potentially could do that. And surely, with Fostrox's mechanism of action, which allows for a higher antigen presentation, it could theoretically work. But since we have the strategy of, uh, initially focusing on a second-line treatment where you have already used your immunotherapy, it is not viable for a second-line combination, but obviously in earlier lines or earlier stages, it could work. But our focus is currently on the second line setting.

Pia Baumann
30:58 - 31:27

Yeah. I think if we look ahead, as Pia is alluding to, if we were to plan a strategic evolution of lifecycle management, it would be logical to combine it, but it would be logical to combine it in the first line, maybe tack it on to a Tecentriq-Avastin combo as a triple. I think that would be the more logical next step. If we were to explore a combination with an IO. That's kind of our thinking.

Jens Lindberg
31:27 - 31:32

Absolutely. But the highest unmet need currently is definitely where there is nothing right now. Yeah.

Unknown 1
31:35 - 31:37

Of course. I appreciate all the details. Thank you.

Operator
31:44 - 31:47

The next question comes from Hans Engblom from EVM. Please go ahead.

Unknown 3
31:51 - 32:27

Hello, guys. Congratulations on the collaboration with Eisai. It's truly a good industrial deal. It has been hardly covered in the media, which is very surprising, but I guess you will do your part in getting them to cover that in terms of financing. Could you elaborate a little on the capital raising process? Uh, and since you are in need of capital to perform the study.

Magnus Christensen
32:29 - 33:08

Thank you for your question. What I can say and guide you on is that, as we stated in a press release as well, we are exploring different alternatives now. And of course, we're looking at different scenarios for equity financing and assistance. As mentioned before, we have been in discussions with several companies, but we cannot provide any further guidance at this stage. Really? Because if we have a deal, then we will inform you when it is signed. We can't say anything before that. So, we are exploring different alternatives at the moment.

Pia Baumann
33:08 - 35:19

And, clearly trying to find, I mean, the best way forward from a value perspective. So, I think that’s why I thank you, Joe, for asking the question, because we are super happy with the engagement from Eisai and the support for the study. While retaining full rights, that also means retaining the full possibility of partnering. So the avenue of partnering is still as open as it used to be before. I would even argue it's actually a better situation for partnering, because now we have the support from a clinical trial supply and the $15-20 million doesn't have to be paid for that. So that's a good step from a partnering discussion. And we are as open to partnering or as able to partner as we were before and the others. But if you partner, and this is the obvious aspect, I know, if you partner, yes, it brings in money, but you are also giving away value. Future value. You're giving away rights to the asset. So, the other avenue is then clearly to identify what sort of equity financing is mine. And that's also a dialogue, an ongoing dialogue we're having in terms of finding perhaps equity financing that allows us to run the study ourselves in full, because clearly we would have the ability and bandwidth to do so. If we are able to secure equity financing, then we retain the full rights and the full future value of the drug. So, we are equally open to both avenues, and both avenues are equally available. On the back of the Eisai trial collaboration, this takes away a cost that we no longer have to worry about. Any further questions?

Operator
35:21 - 35:25

The next question comes from Richard Romanus from Redeye. Please go ahead.

Unknown 3
35:29 - 35:37

Good afternoon. Um, do you have any comments on IBM Bioscience's cancellation of their oncology program?

Pia Baumann
35:38 - 37:23

No, not necessarily. I mean, clearly they had communicated earlier, uh, sort of when they communicated in, now I'm trying to remember, December last year, that they were halting some of their oncology programs and were waiting for the readout of the combination of their DR5 agonist, together with, I believe, FOLFIRI in colorectal cancer. And that would guide them in terms of moving forward, though I'm not sure what details they have shared. But the assumption is that the combination didn't supply them with the data they were hoping for with regards to moving forward with the DR5 agonist in oncology. And if that's the case and they are having some challenges from a financial viewpoint that they need to focus on one area, then it becomes relatively logical for them to not go ahead with the DR5 agonist. And since the drug combination was intended to be used in oncology, it becomes a logical follow-on that they do not continue. We are now having discussions with IBM to determine the impact here, and whether there is a continued opportunity for collaboration with them, or if it is something that reverts back to us. So we're currently discussing with IBM to explore and determine the best way forward for the compound.

Unknown 3
37:26 - 37:30

Do you think sublicensing could be an option?

Pia Baumann
37:31 - 38:42

Yes, I think it's a bit difficult to speculate until we're done. But in a scenario where they decide that they are going to focus on autoimmunity and they don't see a path for advancing in that area, then I think the more logical step would be for the asset to revert back to us. And, we explore alternative licensing options from our side rather than them sublicensing it. That would be my view, but then again, I'm a little bit ahead of it, sort of speculating. We need to follow things through with IgM first. It is important to note that we currently have three patients enrolled in the study with Fostrox and Lenvatinib. They still have patients from their study, which they have paused. So they have a bit of effort to do with regards to handling that side of things as well. The discussions are ongoing. And when we've come to a conclusion, what the next step is, we will clearly communicate that as well.

Unknown 3
38:45 - 39:14

Okay. Going back to the Eisai deal. Um, you just mentioned about 15 to 20 million USD in cost savings. Um, could you clarify that? As you previously mentioned, the guidance for cost is 1 to 2 million per patient. So, does that mean the trial will likely be at the lower half or the lower range of that in the future?

Pia Baumann
39:15 - 41:00

Let's put it this way: the 1 to 1.5 million SEK figure is crucial. Where patients are recruited, and included in the study, is likely to have a significant impact on costs, especially given the differences in costs across various countries. So, the short answer is no, I don't think you can strictly apply the drug element and then determine the cost per patient because there are many factors involved in the total cost. However, not having to pay 15 to 20 million USD for the study is an important factor, especially in the context of partnering and equity financing discussions. So that is a question that is quite critical when you look at partnering or financing a certain program; if you have an uncertainty of 15 to 20 million USD for a study like this, then it clearly presents a challenge, though 'hurdle' may not be the precise term to use. So now, removing that uncertainty, and also having Eisai as part of our team to deliver the study in the best way possible. It's two positives in one go to remove some of the uncertainties.

Unknown 3
41:03 - 41:14

I understand. For the last question, do you intend to provide more readouts from the ongoing Phase 2 study?

Jens Lindberg
41:15 - 41:38

Yes. So, we are closing the study. And again, we were hoping to close it much earlier, but the patients are still on. So we are not going to leave the patients without treatment since it has been so effective. So that is a process that is ongoing to find a solution for them. And then we are going to provide additional treatment data, hopefully somewhere in the beginning of next year.

Unknown 3
41:44 - 41:45

That's all for me. Thanks.

Operator
41:53 - 41:57

The next question comes from Klaas Palin from Carnegie. Please go ahead.

Unknown 3
42:01 - 42:01

Yes.

Unknown 4
42:01 - 42:16

Hello, and thank you for taking my questions. Just to clarify, if I understand you correctly, a local partner deal for Fostrox could still be an option for you. Is that correct?

Unknown 2
42:16 - 42:17

Yes.

Pia Baumann
42:18 - 42:31

And again, my argument, or rather, my point is that removing the cost uncertainty of the drug is beneficial for those discussions.

Unknown 3
42:34 - 42:34

Okay.

Unknown 4
42:34 - 42:51

But such a partner would then be more of a selling company than a developing company. I mean, a fully-fledged pharma is not what you are looking for. You're more or less looking for a seller of drugs then.

Pia Baumann
42:51 - 44:26

I mean, not necessarily. So we're looking for the best potential partner, and that partner is to come on board if we choose the partnering route. As we said, we clearly need to finance the next phase. Equity financing is one option, and retaining full rights is another. The other option is partnering with the best potential sort of deal or agreement with the best possible terms. And if we go down that partnering path now, with that partner, we also want to work from a development perspective locally in the countries where that deal is to be made. And that includes the partner also being part of funding the global phase 2B study in the country where the agreement is made, to put it that way. So, it's not just about commercialization; indeed, whoever we partner with now will also be the commercializing partner, serving as the next step. Now I'm wondering if I was unclear on this one, but I think that it's not just about commercialization. At this stage, any partner will clearly have a role to play from a development perspective locally in the region where the deal is to be made.

Unknown 4
44:29 - 44:40

Perfect. And, out of curiosity, was there a licensing deal on the table with Eisai, if you care to comment on that?

Pia Baumann
44:41 - 46:09

As I mentioned before, and as Magnus alluded to, we communicate those kinds of details only when we have something definitive to announce. But for any sort of licensing deal, whether that is with Eisai or with anyone else, the clinical trial supply and the agreement need to get to a point where it's clear that this is a good study to run. We have supply, etc. The first step that needs to be taken, whether we speak with Eisai or with someone else. And clearly, we have had and we continue to have discussions with Eisai. I mean, they've committed to these first two steps as one option. Clearly, we aim to secure the best possible licensing deal. And I think it's good to remove a hurdle that is seen as a hurdle for other companies. So we can do that first, and then you get to a point where you enter more detailed licensing discussions. It potentially opens up the possibility for other companies as well. Now I'm wondering if that sounded a bit wobbly.

Unknown 3
46:09 - 46:12

Very good. No.

Unknown 4
46:12 - 46:17

Very good answer. Thank you so much. Thank you.

Pia Baumann
46:19 - 46:21

Not I mean, not necessarily. Additional questions.

Operator
46:25 - 46:28

That's all from me. Thank you. From EVM. Please go ahead.

Pia Baumann
46:33 - 46:33

Hans.

Unknown 3
46:34 - 46:47

Hi, Hans. Here again? Yes. I just wanted to know when. When will you decide on the size, meaning the number of patients? When? When do you think that will be done?

Jens Lindberg
46:48 - 47:34

So, I mean, it's more or less done according to the assumptions that we have. We have designed a study that meets the statistical prerequisites for what we aim to achieve, including the potential for accelerated approval and other opportunities. Then obviously, this is partly an adaptive design. So depending on the results going forward, we might increase the number of patients. But that decision will come later. And it's driven only by pre-established statistical decisions. So yeah, I can't say more than that currently. But the design is already set.

Pia Baumann
47:34 - 48:50

And I'll add to that, because we clearly know what the study looks like. And the team has done quite an extensive amount of work from a statistical viewpoint, engaging with the steering committee. The steering committee is super engaged, so we have a very good view and a very strong proposal that we could theoretically share in detail here today. But we will share that when the IND is open. So clearly, we are extremely confident that what we have proposed will be successful with the FDA. But we just need to go through the process of having the IND opened, because that's the date when we know that, okay, all is good. So, rather than sharing something that might change slightly, let's ensure we communicate when we have that finalized. And as I said, the plan to open the IND and the preparations to open the IND this year are progressing nicely.

Unknown 3
48:53 - 48:59

Super. You replied to two questions in one. Thank you very much.

Unknown 5
49:01 - 49:01

Thank you.

Pia Baumann
49:06 - 49:07

Any additional questions?

Operator
49:07 - 49:15

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Unknown 2
49:15 - 49:15

Okay.

Pia Baumann
49:16 - 51:56

Thank you everyone for listening in. And thank you, everyone, for engaging with questions. We received a lot of questions, which we appreciate. To summarize, I'll go back to the slide that I showed before. It feels a bit repetitive at times, but I guess repetition is always good. One thing we have is that we are doing what no one else is doing. And I think it's quite important to emphasize with regards to bringing a targeted or liver-targeted treatment to patients with advanced liver cancer. And since these patients sort of succumb to complications from their primary tumor. The more effective the treatment, the better. The more effective the tumor-killing treatment you can administer locally in the liver, the better. And we've shown quite nicely in the monotherapy and the combination that we do induce DNA damage selectively in the liver. That is translating very nicely into the clinical benefit of time to progression and overall response rate. That is substantially better than what we see with current second line treatment alternatives. As Pia Baumann has commented many times, I think the aspect that excites us the most is the fact that patients are staying on drug and benefiting from treatment for quite long periods. With the longest-running patients now at 26 months, which is exceptionally long for second-line liver cancer, there is a window of opportunity. The competitive landscape is weak. We are at the forefront. So there is an opportunity to move with speed. Be the first approved treatment option. We are progressing nicely in terms of speed with regard to our phase two randomized study that we are planning, and we are receiving considerable enthusiasm and engagement from the scientific community to get there because there is a lack of treatment options. And at the end of the day, what we're trying to tap into is a sizable market opportunity of at least $2.5 billion, with a lack of treatment options, with a lack of resistance to commercial uptake. So with that, thank you for engaging. It's been an eventful quarter three, and we look forward to continuing the acceleration of Fostrox's development. Thank you everyone.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…